Trial · NCT02915302
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Fever (Fever Rate) Following Vaccination With Fluzone Quadrivalent Vaccine | Fluzone Quadrivalent Vaccine, 0.25-mL | 11.31 | 95% Confidence Interval 9.31 to 13.57 | percentage of participants | |
| Percentage of Participants With Fever (Fever Rate) Following Vaccination With Fluzone Quadrivalent Vaccine | Fluzone Quadrivalent Vaccine, 0.5-mL | 12.15 | 95% Confidence Interval 10.12 to 14.42 | percentage of participants | |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.25-mL | A/H1N1 | 214 | 95% Confidence Interval 185 to 247 | Titers (1/dilutions [dil]) |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.5-mL | A/H1N1 | 310 | 95% Confidence Interval 271 to 354 | Titers (1/dilutions [dil]) |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.25-mL | A/H3N2 | 221 | 95% Confidence Interval 191 to 256 | Titers (1/dilutions [dil]) |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.5-mL | A/H3N2 | 332 | 95% Confidence Interval 290 to 380 | Titers (1/dilutions [dil]) |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.25-mL | B Victoria | 261 | 95% Confidence Interval 227 to 299 | Titers (1/dilutions [dil]) |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.5-mL | B Victoria | 348 | 95% Confidence Interval 304 to 398 | Titers (1/dilutions [dil]) |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.25-mL | B Yamagata | 243 | 95% Confidence Interval 213 to 277 | Titers (1/dilutions [dil]) |
| Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies | Fluzone Quadrivalent Vaccine, 0.5-mL | B Yamagata | 349 | 95% Confidence Interval 307 to 397 | Titers (1/dilutions [dil]) |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.25-mL | A/H1N1 | 78.9 | 95% Confidence Interval 75.0 to 82.5 | percentage of participants |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.5-mL | A/H1N1 | 84.1 | 95% Confidence Interval 80.5 to 87.2 | percentage of participants |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.25-mL | A/H3N2 | 81.9 | 95% Confidence Interval 78.1 to 85.3 | percentage of participants |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.5-mL | A/H3N2 | 86.2 | 95% Confidence Interval 82.9 to 89.2 | percentage of participants |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.25-mL | B Victoria | 87.2 | 95% Confidence Interval 83.9 to 90.1 | percentage of participants |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.5-mL | B Victoria | 88.6 | 95% Confidence Interval 85.4 to 91.3 | percentage of participants |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.25-mL | B Yamagata | 87.8 | 95% Confidence Interval 84.5 to 90.6 | percentage of participants |
| Percentage of Participants With Seroconversion (Seroconversion Rate [SCR]) to Influenza Vaccine Antigens | Fluzone Quadrivalent Vaccine, 0.5-mL | B Yamagata | 91.2 | 95% Confidence Interval 88.3 to 93.5 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02915302/results